NNMT inhibitor
5-Amino-1MQ
Cited range Preclinical-heavy
What it is
5-amino-1-methylquinolinium is not a peptide. It inhibits nicotinamide N-methyltransferase (NNMT), an enzyme that methylates nicotinamide and can drain NAD+ salvage in adipose and liver models.
Benefits in plain language
What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.
- Not a classic peptide. It blocks NNMT, an enzyme that can siphon methyl groups and slow fat-cell metabolism.
- The sales pitch is easier fat loss and better NAD-related energy in fat tissue.
- Most of the excitement is mouse and mechanism data. Human fat-loss trials are not the foundation here.
- Often stacked in “metabolic” research lists next to MOTS-c or GLP-1s — that does not make the stack proven.
- The pre-mixed vial with NAD+ and MOTS-c is sold as Mito Prime.
If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.
Mechanism of action
Blocking NNMT is hypothesized to preserve nicotinamide for NAD+ synthesis, alter adipocyte metabolism, and reduce fat-mass accumulation in diet-induced obesity mice. That is a pathway story, not a completed human dose-finding program.
Possible side effects / caveats
Human adverse-event profile is not well established. Methylation-pathway interference is a theoretical long-term question. Capsule products vary in salt form and actual milligrams.
Protocol ranges
| Source tier | Amount | Frequency | Notes |
|---|---|---|---|
| Cited range | 50–150 mg/day | Oral, once daily | Dominant secondary-source window |
| Cited pattern | Half dose for 1–2 days | Then standard amount | Tolerance check used in community writeups, not a trial schedule |